Abd	abdominal
ACTD	dactinomycin
adCTx	adjuvant chemotherapy
Amp	amputation
B	breast
C	cyclophosphamide
CDDP	cisplatin
CI	confidence interval
CTx	chemotherapy
D	doxorubicin
DFS	disease-free survival
DRFI	distant recurrence-free interval
DTIC	dacarbazine
EORTC	European Organization for Research and Treatment of Cancer
EPI	epirubicin
FU	follow-up
G	grade
GEM	gemcitabine
GIST	gastrointestinal stromal tumors
Gy	gray
HCI	high limit of 95% confidence interval
HE	hysterectomy
HN	head and neck
HTx	hyperthermia
HtCTx	histology tailored chemotherapy
IFO	ifosfamide
ivhet	inverse-variance heterogeneity
LCI	low limit of 95% confidence interval
LRFI	local recurrence-free interval
MTX	methotrexate
n.a.	not available
NCDB	National Cancer Database
n.r.	not reported
NaCTx + HTx	neoadjuvant chemotherapy and hyperthermia
NaCTx	neoadjuvant chemotherapy
OR	odds ratio
OS	overall survival
periCTx	perioperative chemotherapy
R	resection rate
RP	retroperitoneal
RT	radiotherapy
S	surgery
T	trunk
Tx	thorax
TXT	docetaxel
U	uterus
V	vincristine
WE	wide excision
Y	year